Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement

• The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.
• It announced second-quarter preliminary net product revenue for WAKIX (pitolisant) of approximately $261 million.
• CEO Jeffrey M. Dayno stated that the record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business.

Shares of Harmony Biosciences Holdings, Inc. (HRMY) drew significant investor attention on Thursday after the company reported its preliminary second-quarter revenue and announced that its CFO, Glenn Reicin, has stepped down to pursue other opportunities effective July 16.

As of this writing, HRMY shares traded over 5% lower on Thursday morning. The stock hit its 200-day moving average (DMA) and bounced back, paring some of the early morning losses.

HRMY’s CFO Transition

Harmony announced that it appointed Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer, to ensure continuity in financial leadership as it searches for a permanent CFO.

Harmony also stated that the CFO’s departure is not due to any disagreement with the firm. “Mr. Reicin’s departure is not the result of any disagreement with the company on any matter relating to its operations, policies or practices, and Harmony does not expect this transition to affect its performance or momentum in any way,” the firm stated.

HRMY Announces Preliminary Figures

The company reaffirmed its full-year 2026 net product revenue guidance of $1 billion to $1.04 billion. It announced preliminary second-quarter (Q2) net product revenue for WAKIX (pitolisant) of approximately $261 million, which it said is a new quarterly revenue record and marks 30% year-over-year growth and 21% quarter-over-quarter growth.

CEO Jeffrey M. Dayno stated that the record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business.

“Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion.”

Harmony is scheduled to report its Q2 results on August 4.

Meanwhile, retail sentiment surrounding HRMY stock on Stocktwits turned ‘neutral’ from ‘bearish’ a day ago, amid moderate chatter.

HRMY shares have lost over 11% this year.

Also Read: AAPL's China Memory Chip Plans Draw National Security Scrutiny — Lawmakers Say Every Memory Chip Purchase Will Subsidize PLA

For updates and corrections, email newsroom[at]stocktwits[dot]com.